These results suggest that inflammatory mediators, such as LTA, LPS, or Il-6, can modulate ovarian cancer progression by changing inflammatory response and expression (Wnt5A-ROR2) patterns. This evidence concerns the gene ROR2 and ovarian carcinoma.